Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians are sometimes faced with difficult diagnostic and therapeutic situations. The disease pathophysiology is partially understood, explaining the lack of predictive factors for occurrence. Different international recommendations for their management have been published: the most recent in 2018 by the European Thyroid Association (ETA) (Ross et al., 2016; Bartalena et al., 2018). The purpose of this paper is to present the essential concepts for their management and to review the literature since 2018.

中文翻译：

---

胺碘酮致甲状腺毒症

胺碘酮诱发的甲状腺毒症 (AIT) 是一种并不少见的内分泌疾病。临床医生有时会面临困难的诊断和治疗情况。疾病的病理生理学被部分理解，解释了缺乏发生的预测因素。针对其管理的不同国际建议已发布：欧洲甲状腺协会 (ETA) 于 2018 年发布了最新建议（Ross 等人，2016 年；Bartalena 等人，2018 年）。本文的目的是介绍其管理的基本概念，并回顾 2018 年以来的文献。